

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,743	08/04/2003	Naoki Yamamoto	TECH-002	6614
24353 7590 02/26/2007 BOZICEVIC, FIELD & FRANCIS LLP 1900 UNIVERSITY AVENUE			EXAMINER	
			PARKIN, JEFFREY S	
SUITE 200 EAST PALO ALTO, CA 94303			ART UNIT	PAPER NUMBER
			1648	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MOI	NTHS	02/26/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)			
Office Action Summers	10/634,743	YAMAMOTO ET AL.			
Office Action Summary	Examiner	Art Unit			
	Jeffrey S. Parkin, Ph.D.	1648			
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with the	e correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>03</u> MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status		•			
1) Responsive to communication(s) filed on 29	Responsive to communication(s) filed on <u>29 November 2006</u> .				
·					
3) Since this application is in condition for allow	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
 4) Claim(s) 7 and 9-11 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 7 and 9-11 is/are rejected. 7) Claim(s) 7 and 9-11 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 					
Application Papers					
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summa Paper No(s)/Mail				
Information Disclosure Statement(s) (PTO/SB/08) Statement(s) (PTO/SB/08) Other:					

Serial No.: 10,634,743 Docket No.: TECH-002
Applicants: Yamamoto, N., et al. Filing Date: 08/04/2003

Detailed Office Action

Status of the Claims

Acknowledgement is hereby made of receipt and entry of the communication filed 29 November, 2006. Claims 1-6, 8, and 12-18 were canceled without prejudice or disclaimer. Claims 7 and 9-11 are currently under examination.

Claim Objections

Claims 7 and 9-11 are objected to because of the following informalities: applicants are advised that all abbreviations should be identified fully the first time they appear in a claim to avoid any confusion or ambiguity. For instance, in claim 7 "HIV-1" should be amended to recite --A human immunodeficiency virus type 1 (HIV-1)--. Appropriate correction is required.

35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 7 and 9-11 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Two separate requirements are set forth under this statute: (1) the claims must set forth the subject matter that applicants regard as their invention; and (2) the claims must particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant.

First, the claims reference a suppression factor with a molecular weight of greater than 100 kDa. The determination of a protein's molecular weight can vary considerably depending upon the method employed (e.g., gel exclusion chromatography; SDS-PAGE; affinity chromatography) and the physicochemical characteristics of the protein (e.g., linear; coiled; highly charged; hydrophobic). when referencing the molecular weight of a protein, applicants should also include the method utilized in the determination (i.e., an HIV-1 infection suppression factor extract wherein said extract has a nominal molecular weight in excess of 100 kDa as determined by Centricon centrifugation). Second, the phrase "wherein the factor is not lost its suppression activity when subjecting to neutralizing antibodies" is nonsensical. Applicants should amend the claim language to clearly set forth the salient characteristics of the claimed subject matter (i.e., wherein the extract comprising the suppression factor does not lose its suppressive activity in the presence of human RANTES,..., neutralizing antisera).

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Scope of Enablement

Claims 7 and 9-11 are rejected under 35 U.S.C. § 112, first paragraph, because the specification does not reasonably enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention

Serial No.: 10/634,743
Applicants: Yamamoto, N., et al.

commensurate in scope with these claims. The claims are directed toward an HIV-1 suppression factor having the recited properties. However, there is no indication from reading the specification that applicants actually prepared a purified factor. In fact, the specification discloses the preparation of a culture supernatant having the recited properties. At no time was the suppressive activity purified to homogeneity.

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." These factors include, but are not limited to: (1) The breadth of the claims; (2) The nature of the invention; (3) The state of the prior art; (4) The level of one of ordinary skill; (5) The level of predictability in the art; (6) The amount of direction provided by the inventor; (7) The existence of working examples; and (8) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. In re Wands, 858 F.2d 731, 737, 8 U.S.P.Q.2d 1400, 1404 (Fed. Cir. 1988).

set forth *supra*, the disclosure fails reproducible method for obtaining a purified HIV-1 suppressive Αt no time does the specification disclose the identification and purification of any particular activity to homogeneity. Thus, the skilled artisan has been asked to guess as to which factor or factors are responsible for the recited antiviral activity. Appropriate amendment of the claim language is required (i.e., A partially purified culture supernatant/extract comprising a human immunodeficiency virus type 1 suppressive factor wherein said factor inhibits HIV-1 R5 viral replication...). Applicants are invited to contact the examiner to discuss suggested allowable revisions to the claim language.

Serial No.: 10/634,743 Applicants: Yamamoto, N., et al.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Office (Office) requires most patent correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Serial No.: 10/634,743 Applicants: Yamamoto, N., et al.

Respectfully,

Jeffrey S. Parkin, Ph.D. Primary Examiner
Art Unit 1648

20 February, 2007